Literature DB >> 18513394

Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumanii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary.

Dora Szabó1, Julia Szentandrássy, Zsuzsa Juhász, Katalin Katona, Károly Nagy, László Rókusz.   

Abstract

INTRODUCTION: Pseudomonas aeruginosa and Acinetobacter baumanii are important nosocomial pathogens with wide intrinsic resistance. However, due to the dissemination of the acquired resistance mechanisms, such as extended-spectrum beta-lactamase (ESBL) and metallo beta-lactamase (MBL) production, multidrug resistant strains have been isolated more often. CASE
PRESENTATION: We report a case of a Hungarian tourist, who was initially hospitalized in Egypt and later transferred to Hungary. On the day of admission PER-1-producing P. aeruginosa, PER-1 producing A. baumannii, SHV-5-producing Klebsiella pneumoniae and VIM-2-producing P. aeruginosa isolates were subcultured from the patient's samples in Hungary. Comparing the pulsed-field gel electrophoresis (PFGE) patterns of the P. aeruginosa strains from the patient to the P. aeruginosa strains occurring in this hospital, we can state that the PER-1-producing P. aeruginosa and VIM-2-producing P. aeruginosa had external origin.
CONCLUSION: This is the first report of PER-1-producing P. aeruginosa,and PER-1-producing A. baumanii strains in Hungary. This case highlights the importance of spreading of the beta-lactamase-mediated resistance mechanisms between countries and continents, showing the importance of careful screening and the isolation of patients arriving from a different country.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18513394      PMCID: PMC2430584          DOI: 10.1186/1476-0711-7-12

Source DB:  PubMed          Journal:  Ann Clin Microbiol Antimicrob        ISSN: 1476-0711            Impact factor:   3.944


Introduction

Pseudomonas aeruginosa and Acinetobacter baumanii are very important nosocomial pathogens mainly in intensive care units, being responsible for various types of infections with more and more limited therapeutic options [1]. The P. aeruginosa have significant intrinsic resistance to antibiotics [2]. Therefore, the antipseudomonal beta-lactams such as ticarcillin, piperacillin, ceftazidime, cefepime, aztreonam, and the carbapenems have an important therapeutic value. Three mechanisms of beta-lactam resistance are predominant: production of beta-lactamases, loss of outer membrane proteins and up-regulation of efflux pumps. Most strains of P. aeruginosa which are resistant to third-generation cephalosporins produce a chromosomally mediated molecular class C beta-lactamase, the AmpC enzyme [2]. However, acquired beta-lactamases encoded by mobile genetic elements are important resistance mechanism in P. aeruginosa and in Acinetobacter spp. as well. Acquired resistance to beta-lactams can lead to therapeutic failure, especially when it is associated with resistance to other classes of drugs, such as aminoglycosides and fluoroquinolones. Among these enzymes acquired, PER (Pseudomonas extended resistance), a class A extended-spectrum beta-lactamase (ESBL), occurring less frequently has clinical importance by conferring resistance to oxyimino beta-lactams [3]. Poor outcome as a result of infection caused by PER-1 producers has been reported [4]. The also acquired metallo beta-lactamases (MBLs) of molecular class B can cause resistance to all beta-lactams except monobactam. The genes of MBLs are usually part of class I integron together with gene cassettes encoding resistance genes. Several types of MBL enzymes have been identified in P. aeruginosa among which the VIM-type enzymes appear to be the most prevalent [5]. Here we report the first detection of PER-producing P. aeruginosa, A. baumannii isolates and VIM-producing P. aeruginosa in Hungary from a patient, who was hospitalized in Egypt and transferred to Hungary. This work illustrates the dissemination of bacteria carrying PER-type ESBL and VIM-type MBL enzymes.

Case presentation

In April, 2006 a 53-year-old Hungarian tourist was involved in a severe terror-attack in Egypt. He was initially hospitalized because of his burn, mechanical injuries and sepsis syndrome in Egypt. Five days later he was transferred in comatose, hypoxic and hypothermic condition to the Burn Unit of State Health Center, Budapest, Hungary. On the day of admission, bacterial cultures taken from burn wound. Based on the different colony morphology and antibiotic susceptibility patterns three different P. aeruginosa strains – an ESBL-producing P. aeruginosa (PA1), an imipenem-resistant P. aeruginosa (PA2), an MBL-producing P. aeruignosa (PA3), were observed and furthermore ESBL-producing Klebsiella pneumoniae (ESBL-KP), methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis (EF) were isolated. Next day ESBL-producing A. baumanii (ESBL-AB) and PA2 were cultured from the patient's canul. During his hospitalization from his nose PA1, ESBL-AB, ESBL-KP, MRSA, from his throat PA1, ESBL-AB, ESBL-KP, from his trachea PA3, ESBL-AB, ESBL.KP,-MRSA and from his wound PA1, PA3, ESBL-AB, ESBL-KP, MRSA and EF were isolated. Blood cultures were taken nine occasions and PA1, ESBL-KP, MRSA and EF were subcultured. The patient received adequate supportive treatment and empirically cefepime, subsequently meropenem and vancomycin were administered intravenously at high dosage. The aminoglycosides were synergy resistant. On the 8th day of the hospitalization in Hungary the patient died. The isolates were identified by VITEK 2 (BioMérieux, Marcy l'Etoile, France). On a routine antibiogram synergy was observed between amoxycillin/clavulanic acid and cefepime or ceftazidime disks (Oxoid, Basingstoke, Hampshire, United Kingdom) in K. pneumoniae and in A. baumanii strains but no synergy was observed in P. aeruginosa strains. The minimum inhibitory concentrations (MICs) of the antimicrobial agents were determined by E-test (AB Biodisk, Solna, Sweden) and by using the interpretative criteria of the Clinical and Laboratory Standards Institute [6]. Pulsed-field gel electrophoresis (PFGE) of the SpeI-digested (New England Biolab, Beverly, MA) genomic DNA of P. aeruginosa was performed and analyzed as described previously [7]. Isoelectric focusing (IEF) was performed, as described previously [8]. In the PCR assays primers specific to blaTEM [9], blaSHV [9], blaPER [10], blaOXAs [11], blaIMP, blaVIM and blaclassI genes [12] were used. The nucleotide sequences were determined using the ABI 3100 Genetic Analyzers (Applied Biosystems, Foster City, CA). Sequences were analyzed using NCBI BLAST search. Three different antibiotic susceptibility patterns were observed in P. aeruginosa strains isolated from the patient on the day of admission (Table 1). All of them were resistant to cephalosporins. The PA1 P. aeruginosa strain was sensitive only to carbapenems, the other P. aeruginosa strain (PA2) was sensitive only to meropenem and both PA1 and PA2 were resistant to all the other tested antibiotics. The third P. aeruginosa (PA3) strain was sensitive to aztreonam and netilmicin and resistant to the all cephalosporins and carbepenems. However, the imipenem MIC value decreased in the presence of EDTA from > 256 to 12 μg/ml suggesting the presence of an MBL enzyme. The A. baumanii isolate was resistant to all cephalosporins and aztreonam, but the ceftazidime and cefotaxime MIC values decreased in the presence of clavulanic acid suggesting the presence of an ESBL enzyme. The K. pneumoniae strain had also ESBL phenotype based on the MIC values and it was sensitive to carbapenems, amikacin and ciprofloxacin as well.
Table 1

The antibiotic susceptibility of P. aeruginosa, A. baumanii and K. pneumoniae strains.

Antimicrobial agentsMIC values (μg/ml)

P. aeruginosa (PA1)P. aeruginosa (PA2)P. aeruginosa (PA3)A. baumaniiK. pneumoniae
Ceftazidime> 256> 256> 256> 256> 256
Ceftazidime/clavulanic acid> 4> 4> 4< 0.643
Cefotaxime> 32> 32> 32> 32> 32
Cefotaxime/clavulanic acid> 1> 1> 10.230.38
Ceftriaxone> 256> 256> 256> 256> 256
Piperacillin/tazobactam> 256> 256> 256> 256> 256
Cefepime> 32> 32> 32> 32> 32
Aztreonam> 64328> 64> 64
Imipenem232> 25611
Imipenem+EDTA1.532121.5< 1
Meropenem0.251> 320.380.25
Amikacin> 2566> 256481.5
Gentamicin16> 256> 25632> 256
Netilmicin> 32> 3221> 32
Tobramycin> 256> 256323224
Ciprofloxacin> 32> 32> 32> 321
The antibiotic susceptibility of P. aeruginosa, A. baumanii and K. pneumoniae strains. The PCR and sequencing results are summarized in Table 2. TEM-1 genes were identified in A. baumanii and K. pneumoniae. OXA genes were recognized in PA1 and PA3 strains. PER-1 genes were found in PA1 and A. baumanii isolates and SHV-5 was found in K. pneumoniae. Only the PA3 isolate harbored the VIM-2 gene. The OXA-10 and VIM-2 genes were located on the same class I integrons, as the sequencing result of class I integron showed.
Table 2

The characteristics of the isolated Gram-negative strains.

TEM PCRSHV PCRPER PCROXA PCRVIM PCRPFGEpI(s)
P. aeruginosa (PA1)negativenegativePER-1OXA-10negativeA type5.3, 6.1, 8.0
P. aeruginosa (PA2)negativenegativenegativenegativenegativeB type8.0
P. aeruginosa (PA3)negativenegativenegativeOXA-1VIM-2C type5.3, 7.4, 8.0
A. baumaniiTEM-1negativePER-1negativenegativeND5.3, 5.4, > 8.5
K. pneumoniaeTEM-1SHV-5negativenegativenegativeND5.4, 8.2

ND: not determined

The characteristics of the isolated Gram-negative strains. ND: not determined According to IEF test results, all the isolates contained β-lactamases. Isoelectric focusing confirmed the expression of PER-1 (pI 5.3), TEM-1 (pI 5.4), OXA-1 (pI 7.4), OXA-10 (pI 6.1), SHV-5 (pI 8.2), VIM-2 (pI 5.3) and the chromosomal AmpC cephalosporinase (pI 8 or > 8.5) enzymes in the different strains (Table 2). The three P. aeruginosa isolates, PA1, PA2 and PA3, showed three different PFGE patterns (data not presented) suggesting that they belonged to different clones (Table 2). Comparing these PFGE patterns to six other P. aeruginosa strains occurring in this Hungarian hospital during the same period, no similarity was found suggesting the external origin of PA1, PA2 and PA3.

Discussion

Based on the antibiotic susceptibilities, IEF and the sequencing result we can state that the PA1 strain and the A. baumanii strain produced PER-1 ESBL enzyme. The A. baumanii strain also produced TEM-1 and the PA1 strain OXA-10 broad-spectrum β-lactamase. The PA2 strain produced only chromosomal AmpC cephalosporinase as suggesting that loss of OprD was responsible for the imipenem resistance. The PA3 strain produced the OXA-1 broad-spectrum β-lactamase and the VIM-2 MBL enzyme. The K. pneumoniae strain produced SHV-5 and TEM-1 enzyme. According to the type of ESBL enzyme produced by different bacteria species SHV- TEM- and CTX-M type ESBL-producing Klebsiella spp. and Escherichia coli strains have been isolated in Hungary so far [13,14] – while in Egypt the ESBL phenotype has been observed in K. pneumoniae and CTX-M-type ESBL in E. coli strains [15,16]. The PER-1 beta-lactamase has been considered to be significant only in Turkey for years [17]. However, the PER-1 beta-lactamase found mainly in P. aeruginosa has been detected in many countries such as Turkey, France, Belgium, Spain, Italy, Poland, Romania, Japan and South Korea until now [10,18-25]. The PER-1 production in Acinetobacter spp. was observed more often in Turkey and in Korea [4,17,26,27]. According to our knowledge this is the first report of PER-1-producing P. aeruginosa and PER-1-producing A. baumanii in Hungary and since that other strains of PER-1 producing P. aeruginosa have been isolated [28]. Several types of MBL enzymes – IMP-type, VIM-type, SPM-1, GIM-1, SIM-1 – have been identified in P. aeruginosa [5]. The VIM enzymes are the most common in Europe [29]. The VIM-2 enzyme detected in this case has been previously found in several species worldwide and it seems to be the most prevalent allelic form [30-35]. In Hungary VIM-producing P. aeruginosa strains have been isolated but in Egypt MBL-producing strains have not been reported until now [36,37]. Furthermore the result of the PFGE analysis of the PA1, PA2 and PA3 confirms, that the three P. aeruginosa strains – the PER-1 producing P. aeruginosa (PA1), the OprD-loss P. aeruginosa (PA2) and VIM-2-producing P. aeruginosa (PA3) strains – had external origin and could be transferred from Egypt to Hungary. The PER-1 producing P. aeruginosa and A. baumanii strains disappeared from the hospital, no more infections have been detected with these strains since then. The emergence and subsequently spread of PER-producing and MBL-producing strains are alarming. Supposing, that these resistance mechanisms might also exist in other countries the dissemination of PER-enzyme could be more prevalent over the world, particularly due to the unsolved problem of routine screening for ESBL-production in P. aeruginosa strains. The CLSI recommendation for screening the ESBL-production in different bacteria species is uncomplete, exist just for Klebsiella spp. and Escherichia coli strains [6]. In conclusion, this work confirms the emergence of PER-1-producing P. aeruginosa and A. baumannii isolate, VIM-2 producing P. aeruginosa strains in Hungary. Furthermore it illustrates the possibility of the inter-country and the inter-continent spread of the beta-lactamase-mediated resistance mechanisms. Our study features the intercontinental spread of antimicrobial resistance, showing the importance of careful screening and the isolation patients arriving from a different country.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LR and ZJ provided clinical care, literature search and edited the manuscript, JS and KK identified the bacteria, performed the antibiotic susceptibility tests, DS carried out the molecular studies, characterized the bacteria and drafted the manuscript, NK drafted the manuscript. All authors read and approved the final manuscript.

Consent

Written informed consent was obtained from the patient's relative for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
  35 in total

1.  Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae.

Authors:  D L Paterson; L B Rice; R A Bonomo
Journal:  Clin Microbiol Infect       Date:  2001-12       Impact factor: 8.067

2.  High prevalence of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter spp. in Korea.

Authors:  Dongeun Yong; Jong Hee Shin; Sinyoung Kim; Youngsik Lim; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Evolution of an integron carrying blaVIM-2 in Eastern Europe: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Timothy R Walsh; Mark A Toleman; Waleria Hryniewicz; Peter M Bennett; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

4.  IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate.

Authors:  Jean-Denis Docquier; Maria Letizia Riccio; Claudia Mugnaioli; Francesco Luzzaro; Andrea Endimiani; Antonio Toniolo; Gianfranco Amicosante; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum beta-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa.

Authors:  S Y Essack; L M Hall; D G Pillay; M L McFadyen; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Molecular typing indicates an important role for two international clonal complexes in dissemination of VIM-producing Pseudomonas aeruginosa clinical isolates in Hungary.

Authors:  Balázs Libisch; Joseph Watine; Boglárka Balogh; Mária Gacs; Mónika Muzslay; Gitta Szabó; Miklós Füzi
Journal:  Res Microbiol       Date:  2008-01-11       Impact factor: 3.992

7.  Identification of PSE and OXA beta-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism.

Authors:  Frédéric Bert; Catherine Branger; Nicole Lambert-Zechovsky
Journal:  J Antimicrob Chemother       Date:  2002-07       Impact factor: 5.790

8.  Metallo-beta-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii.

Authors:  Jing-Jou Yan; Wen-Chien Ko; Chin-Luan Chuang; Jiunn-Jong Wu
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

9.  Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy.

Authors:  Laura Pagani; Elisabetta Mantengoli; Roberta Migliavacca; Elisabetta Nucleo; Simona Pollini; Melissa Spalla; Rossana Daturi; Egidio Romero; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000.

Authors:  Christophe De Champs; Laurent Poirel; Richard Bonnet; Danielle Sirot; Catherine Chanal; Jacques Sirot; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more
  12 in total

1.  Dissemination of a class I integron carrying VIM-2 carbapenemase in Pseudomonas aeruginosa clinical isolates from a hospital intensive care unit in Annaba, Algeria.

Authors:  Meriem Touati; Seydina M Diene; Mazouz Dekhil; Abdelghani Djahoudi; Abdelkarim Racherache; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

2.  Identification of blaOXA-₅₁-like, blaOXA-₅₈, blaDIM-₁, and blaVIM carbapenemase genes in hospital Enterobacteriaceae isolates from Sierra Leone.

Authors:  Tomasz A Leski; Umaru Bangura; David H Jimmy; Rashid Ansumana; Stephen E Lizewski; Robert W Li; David A Stenger; Chris R Taitt; Gary J Vora
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

3.  Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China.

Authors:  Y Chen; M Sun; M Wang; Y Lu; Z Yan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-06       Impact factor: 3.267

4.  Identification of VIM-2-producing Pseudomonas aeruginosa from Tanzania is associated with sequence types 244 and 640 and the location of blaVIM-2 in a TniC integron.

Authors:  Sabrina Moyo; Bjørg Haldorsen; Said Aboud; Bjørn Blomberg; Samuel Y Maselle; Arnfinn Sundsfjord; Nina Langeland; Ørjan Samuelsen
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

5.  Identification of two multidrug-resistant Pseudomonas aeruginosa clonal lineages with a countrywide distribution in Hungary.

Authors:  Balázs Libisch; Boglárka Balogh; Miklós Füzi
Journal:  Curr Microbiol       Date:  2008-10-23       Impact factor: 2.188

6.  Molecular characterization of multidrug resistant hospital isolates using the antimicrobial resistance determinant microarray.

Authors:  Tomasz A Leski; Gary J Vora; Brian R Barrows; Guillermo Pimentel; Brent L House; Matilda Nicklasson; Momtaz Wasfy; Mohamed Abdel-Maksoud; Chris Rowe Taitt
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

7.  Molecular Detection of Adefg Efflux Pump Genes and their Contribution to Antibiotic Resistance in Acinetobacter baumannii Clinical Isolates.

Authors:  Rasoul Kaviani; Iman Pouladi; Mohammad Niakan; Reza Mirnejad
Journal:  Rep Biochem Mol Biol       Date:  2020-01

8.  Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-β-lactamases.

Authors:  Maria F Mojica; S Graciela Mahler; Christopher R Bethel; Magdalena A Taracila; Magda Kosmopoulou; Krisztina M Papp-Wallace; Leticia I Llarrull; Brigid M Wilson; Steven H Marshall; Christopher J Wallace; Maria V Villegas; Michael E Harris; Alejandro J Vila; James Spencer; Robert A Bonomo
Journal:  Biochemistry       Date:  2015-05-12       Impact factor: 3.162

9.  Characterization of antibiotic resistance profiles in Pseudomonas aeruginosa isolates from burn patients.

Authors:  Asma Tchakal-Mesbahi; Merzak Metref; Vijay K Singh; Marianna Almpani; Laurence G Rahme
Journal:  Burns       Date:  2021-03-17       Impact factor: 2.744

Review 10.  Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.

Authors:  András Fodor; Birhan Addisie Abate; Péter Deák; László Fodor; Ervin Gyenge; Michael G Klein; Zsuzsanna Koncz; Josephat Muvevi; László Ötvös; Gyöngyi Székely; Dávid Vozik; László Makrai
Journal:  Pathogens       Date:  2020-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.